Chimerix, Inc. (CMRX)

[dirkv]

https://finance.yahoo.com/news/chimerix-announces-management-updates-210000639.html

[ernie44]

wassa matter witt dis dang ting

[ernie44]

expect something ? on wednesday

[Rapture2020]

Expecting big things tomorrow!

[ernie44]

nice move----CMRX

Should be ex-lax

[ernie44]

Lets not rely on the democrats who think the world owes them a living

[ernie44]

alas, the greeks speak a different language so its all greek to me

[ernie44]

GREAT....... we may see over the moon $5 again

[H8ster]

Chimerix to present Phase 1 data for CMX521 at the 31st annual ISAR, The International Conference on Antiviral Research June 11th-June 15th 2018.

Q1 CC

"Details of the discovery and preclinical development of CMX521 will be presented next month at the International Conference on Antiviral Research. Our ongoing Phase 1 studies are designed to evaluate the pharmacokinetics, safety and tolerability of this novel nucleoside. Data from Phase 1 will allow us to choose optimize dosing regimens to take into Phase 2 efficacy studies in 2019."

"In late 2017, we initiated our first time in human study of CMX521, a nucleoside analog identified from our chemical library as a potential treatment and/or prevention for norovirus. We see this as a great commercial opportunity, as there are currently no approved therapies for the treatment of chronic norovirus infection or for use as a prevention strategy to limit the spread of an outbreak."………….

"Norovirus represents a large and costly unmet need. Each year, there are over 700 million cases resulting in 219,000 deaths. There’s also a significant economic toll, as the cost associated with norovirus is over $60 billion a year. And it’s not just a cruise ship virus, as it frequently impacts long-term care facilities and hospitals, causing ward shutdowns and infections among patients and health care providers.

Approaching the different prevention market segments will include looking at a number of important variables depending upon the setting. For example, in a norovirus outbreak, where there’s central area of control, such as in military facilities, hospitals or medical care settings, a protocol for use can be put in place to quickly disseminate an antiviral for preventing the further spread of this highly contagious virus.

We’ve already done exploratory market research with long-term care facilities, who are very interested in the CMX521 product profile, indicating that the product could have utility not only for preventing infection in patients, but also protecting staff."

[H8ster]

Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

Address Congressional Subcommittee

DURHAM, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C.

The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.

“Unfortunately, the threat of a biological event impacting the United States has never been more real,” said Dr. Berrey. “Our private-public partnerships over the last 15 years, particularly with BARDA, have been critical to the survival and progression of our smallpox program with brincidofovir. We commend the Committee for bipartisan collaboration on the PAHPA reauthorization. Companies like ours rely on the existence of a government market for medical countermeasures to sustain the long-term investment of researching and developing these therapies, which provide a critical bulwark against biological threats.”……………...

[H8ster]

What new FDA designation means for Durham's Chimerix

Durham-based biopharma Chimerix (Nasdaq: CMRX) has banked a new designation from the U.S. Food and Drug Administration.

The FDA granted Chimerix Orphan Drug Designation for its lead drug candidate brincidofovir – known as brinci – for the treatment of smallpox. Benefits of the designation include the likes of development incentives and tax credits.

While members of the Chimerix team were traveling and unavailable for interviews, a company representative said the significance of the designation is two-fold.

“First, it underscores the critical need for the research and development of lifesaving medical countermeasures in the event of a smallpox outbreak, whether naturally occurring or the result of a bioterror event,” the representative noted. “Second, it provides many benefits, including a waiver of the FDA Prescription Drug User Fee Act.”…………………...


FDA designation

[H8ster]

Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox.

Chimerix has been working with the Biomedical Advanced Research and Development Authority (BARDA) since 2011 to develop brincidofovir as a medical countermeasure for smallpox, demonstrating improved survival rates following confirmed orthopoxvirus infections in multiple animal models.

“We are very pleased to have received Orphan Drug Designation from the FDA for brincidofovir as a treatment for smallpox,” said M. Michelle Berrey, MD, MPH, President and Chief Executive Officer of Chimerix. “Though declared eradicated in the late 1970s, smallpox, whether natural or synthetic, continues to be a potential global threat in today’s interconnected world. We are committed to completing the development program for brincidofovir as a much-needed treatment option for smallpox, in close collaboration with BARDA and FDA.”

Orphan Drug Designation

[H8ster]

Looking good from here!

[Shaka_Zulu]

Break out to 7.50?

Might enter at 5.25

[ernie44]

snowed in cabin dwellers are taking profits...causing mm to cover

[ernie44]

almost time to get more cheap shares

[ernie44]

CHARTS GALLORE


https://stockcharts.com/c-sc/sc?s=CMRX&p=D&b=5&g=0&i=p29743012051&r=1347046823097

[ernie44]

not worth the gamble right now---see if santa sells at 3.77

[ernie44]

some rookie wants to buy at 1.05, while tousands and tousands hold on

[ernie44]

level 2 had a early am offer of $2,000.00

[ernie44]

am out in the 5's

[ernie44]

News from the great white north proposes a new trade war

RUSSKIES

[ernie44]

5 bucks; 5 bucks

[ernie44]

4.67

[ernie44]

hye mom.. we got comps

[Panzer]

This sucks?

[kwisatzhaderach]

explain

[Panzer]

Unleash the hounds!! Boom! $8 in May.

[ernie44]

healthy trades--but unknown on AVA or i-hub

[ernie44]

many believe the new pres elect will move the market


can hardly wait for Friday

[ernie44]

yes, doing the 'bounce-around' dance

[DewDiligence]

Most biotechs are :- )

[ernie44]

trading briskly today--insiders and mm's

[DewDiligence]

CMRX had $289.5M of cash/investments at 9/30/15—a burn of $12.0M since 6/30/16:

http://finance.yahoo.com/news/chimerix-announces-third-quarter-2016-120000229.html

[ernie44]

modesty might be a virtue on CMRX

if interest rates are inc. by the fed--we might see tripple digit gains
like in the olde days

[Donaltrompeta]

Not there yet but soon

[ernie44]

girlfriend--- I SEE THAT CMRX breaking out

CMRX breaking out of its channel here

[girlfriend]

CMRX breaking out of its channel here….nice volume.

[ernie44]

seen that before

let the games begin

[DewDiligence]

CEO bought $100K of stock on 8/29/16:

https://www.sec.gov/Archives/edgar/data/1117480/000120919116139293/xslF345X03/doc4.xml

[ernie44]

same thing in the coffee business
eg green mtn coffee

when the picking ends

go CMRX

[girlfriend]

I am usually out before the FDA decision or at least a good chunk of any position. Stops are no good when the stock crashes….

[ernie44]

aren't we all investors parking our money

phase 3's are always tricky

[girlfriend]

Its all yours…moderator. I'm just here for a ride….hopeful

[ernie44]

Piper Jaffray Cos. Analysts Give Chimerix Inc. (CMRX) a $12.00 Price Target

we should apply for mod. -- the only ones here

[girlfriend]

Always is…..at least in my book.

Do notice increase in institutional holdings over past weeks…..since the stabilization.

Just holding a few from the low 4's hoping for a squeeze no big deal.

[ernie44]

the key operative word is guidance

and I don't see that

[ernie44]

Iam now immune to mamma boys, and bs`ers

[ernie44]

we been getting the SNOW-JOB too long now

listen to the conferrence calls---they are grasping at straws with more troubling solutions

[girlfriend]

I don't see that…..but thanks.